-
Diabetes and Obesity – WHO Updates Core Essential Medicines List, Charting a New Direction
Nov , 18 2025
Diabetes and obesity have emerged as two of the most urgent health challenges facing the world today. A staggering 800 million people were living with diabetes in 2022, with half remaining untreated. ...
read more
-
A Comprehensive Analysis: Semaglutide API, R&D and Manufacturing in China
Dec , 23 2025
With the growing global focus on GLP-1 based therapies, China's role in this field has become increasingly pivotal. Core Concept: What is Semaglutide API? Semaglutide API (Semaglutide Active Ingredien...
read more
-
Market Insight: ECO 2026 Highlights Orforglipron's Potential to Reshape the $100B Oral GLP-1 Market
May , 19 2026
The European Congress on Obesity (ECO 2026) has concluded, but the excitement surrounding Orforglipron (LY3502970) continues to reverberate throughout the global pharmaceutical industry. For millions ...
read more
-
Orforglipron vs. Semaglutide vs. Tirzepatide: The Ultimate 2026 Weight Loss Drug Comparison
May , 21 2026
1. Introduction: The GLP-1 Evolution The weight loss pharmaceutical market has dramatically shifted with the 2026 FDA approval of Orforglipron (Foundayo). This new oral, non-peptide agonist challenges...
read more
IPv6 network supported
English
中文
français
Deutsch
русский
español
português
العربية
日本語
한국의
Türkçe
